ArticleLeukemia2012
Long-term WT1 peptide vaccination for patients with acute myeloid leukemia with minimal residual disease.
Article in Leukemia, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01513109 (A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic), which is not on this map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Study to Assess the Safety and Immunogenicity of WT1-A10 + AS01B Antigen-Specific Cancer Immunotherapeutic (ASCI) Combined With Infusions of ex Vivo Regulatory T Cells Depleted T Lymphocytes in in Vivo Regulatory T Cells Depleted Patients as Post-consolidation Therapy for Adult Patients With WT1-positive Acute Myeloid Leukemia (AML) in CR1 (for High Risk Patients) or in CR2 or CR3 Who Are Not Eligible for Allogeneic Stem Cell Transplantation (SCT).
Who cites it
29 citing papers in PubMed.
- First-in-human study of WT1 recombinant protein vaccination in elderly patients with AML in remission: a single-center experience.Cancer immunology, immunotherapy : CII · 2022Trial
- Phase I/II clinical trial of a Wilms' tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer.Cancer immunology, immunotherapy : CII · 2019Trial
- Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses.British journal of haematology · 2014Trial
- Spontaneous high clonal expansion of Wilms' tumor gene 1-specific cytotoxic T-lymphocytes in patients with Wilms' tumor gene 1-expressing solid tumor.Cancer immunology, immunotherapy : CII · 2024Article
- UnderstandingCancers · 2023Article
- Review
- Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.Cancer treatment and research · 2022Article
- Therapeutic vaccination against leukaemia via the sustained release of co-encapsulated anti-PD-1 and a leukaemia-associated antigen.Nature biomedical engineering · 2021Article
- Immunotherapy in Acute Myeloid Leukemia: Where We Stand.Frontiers in oncology · 2021Review
- Article
- HLA class I-restricted T cell epitopes isolated and identified from myeloid leukemia cells.Scientific reports · 2019Article
- Cancer immune therapy for myeloid malignancies: present and future.Seminars in immunopathology · 2019Review
- Calreticulin is an effective immunologic adjuvant to tumor-associated antigens.Experimental and therapeutic medicine · 2017Article
- High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.Journal of hematology & oncology · 2017Article
- Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine.Future science OA · 2016Article
- Life after transplant: are we becoming high maintenance in AML?Bone marrow transplantation · 2016Review
- Wilms tumor 1 mutations in the pathogenesis of acute myeloid leukemia.Haematologica · 2016Review
- Wilms tumor 1 peptide vaccination after hematopoietic stem cell transplant in leukemia patients.Stem cell investigation · 2016Review
- The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Journal for immunotherapy of cancer · 2016Article
- Two distinct effector memory cell populations of WT1 (Wilms' tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients.Cancer immunology, immunotherapy : CII · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
22157809What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.